

COVID-19 IN PATIENTS WITH CANCER

Patients with cancer are highly vulnerable to COVID-19, and this vulnerability is determined by the type of cancer they have and whether they are under active anticancer treatment. The disproportionate burden of COVID-19 in cancer patients is even more pronounced among those belonging to racial or ethnic minorities and other medically underserved populations. Listed below are some recent examples highlighting the multifaceted impact of COVID-19 on patients with cancer:

47% vs 24%

The **hospitalization rates for COVID-19 patients with cancer** were higher than for COVID-19 patients without cancer, 47 percent versus 24 percent.

28% vs 16%

Twenty-eight-day mortality rate in cancer patients with COVID-19 was higher than in cancer patients without COVID-19, 28 percent versus 16 percent.

9% vs 3%

More **Black patients with breast cancer and COVID-19 required mechanical ventilation** than white patients with breast cancer and COVID-19, 9 percent versus 3 percent.

34% vs 20%

COVID-19 patients with active cancer were more likely to die than those with no history of cancer, 34 percent versus 20 percent.

45% vs 12%

Mortality rate for cancer patients with COVID-19 was 45 percent for those who were **receiving an anti-CD20 anticancer treatment** compared to 12 percent for those who were receiving an anti-Janus Kinase inhibitor anticancer therapy.

16% vs 3%

Sixteen percent of **COVID-19 patients with lung cancer who required admission to an intensive care unit** compared to 3 percent of COVID-19 patients without lung cancer.